Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

433 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Advances in myelodysplastic/myeloproliferative neoplasms.
Prakash S, Arber DA, Bueso-Ramos C, Hasserjian RP, Orazi A. Prakash S, et al. Virchows Arch. 2023 Jan;482(1):69-83. doi: 10.1007/s00428-022-03465-7. Epub 2022 Dec 5. Virchows Arch. 2023. PMID: 36469102 Review.
Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
Wang SA, Hasserjian RP, Fox PS, Rogers HJ, Geyer JT, Chabot-Richards D, Weinzierl E, Hatem J, Jaso J, Kanagal-Shamanna R, Stingo FC, Patel KP, Mehrotra M, Bueso-Ramos C, Young KH, Dinardo CD, Verstovsek S, Tiu RV, Bagg A, Hsi ED, Arber DA, Foucar K, Luthra R, Orazi A. Wang SA, et al. Blood. 2014 Apr 24;123(17):2645-51. doi: 10.1182/blood-2014-02-553800. Epub 2014 Mar 13. Blood. 2014. PMID: 24627528 Free PMC article.
Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group.
Kanagal-Shamanna R, Orazi A, Hasserjian RP, Arber DA, Reichard K, Hsi ED, Bagg A, Rogers HJ, Geyer J, Darbaniyan F, Do KA, Devins KM, Pozdnyakova O, George TI, Cin PD, Greipp PT, Routbort MJ, Patel K, Garcia-Manero G, Verstovsek S, Medeiros LJ, Wang SA, Bueso-Ramos C. Kanagal-Shamanna R, et al. Mod Pathol. 2022 Apr;35(4):470-479. doi: 10.1038/s41379-021-00961-0. Epub 2021 Nov 13. Mod Pathol. 2022. PMID: 34775472 Free PMC article.
De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
Hasserjian RP, Campigotto F, Klepeis V, Fu B, Wang SA, Bueso-Ramos C, Cascio MJ, Rogers HJ, Hsi ED, Soderquist C, Bagg A, Yan J, Ochs R, Orazi A, Moore F, Mahmoud A, George TI, Foucar K, Odem J, Booth C, Morice W, DeAngelo DJ, Steensma D, Stone RM, Neuberg D, Arber DA. Hasserjian RP, et al. Am J Hematol. 2014 Nov;89(11):E193-9. doi: 10.1002/ajh.23808. Epub 2014 Jul 31. Am J Hematol. 2014. PMID: 25042343 Free article.
Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified.
Wang SA, Tam W, Tsai AG, Arber DA, Hasserjian RP, Geyer JT, George TI, Czuchlewski DR, Foucar K, Rogers HJ, Hsi ED, Bryan Rea B, Bagg A, Dal Cin P, Zhao C, Kelley TW, Verstovsek S, Bueso-Ramos C, Orazi A. Wang SA, et al. Mod Pathol. 2016 Aug;29(8):854-64. doi: 10.1038/modpathol.2016.75. Epub 2016 May 13. Mod Pathol. 2016. PMID: 27174585 Free article.
Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia.
Geyer JT, Tam W, Liu YC, Chen Z, Wang SA, Bueso-Ramos C, Oak J, Arber DA, Hsi E, Rogers HJ, Levinson K, Bagg A, Hassane DC, Hasserjian RP, Orazi A. Geyer JT, et al. Mod Pathol. 2017 Sep;30(9):1213-1222. doi: 10.1038/modpathol.2017.45. Epub 2017 May 26. Mod Pathol. 2017. PMID: 28548124 Free article.
Correction to: Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group.
Kanagal-Shamanna R, Orazi A, Hasserjian RP, Arber DA, Reichard K, Hsi ED, Bagg A, Rogers HJ, Geyer J, Darbaniyan F, Do KA, Devins KM, Pozdnyakova O, George TI, Cin PD, Greipp PT, Routbort MJ, Patel K, Garcia-Manero G, Verstovsek S, Medeiros LJ, Wang SA, Bueso-Ramos C. Kanagal-Shamanna R, et al. Mod Pathol. 2022 May;35(5):705. doi: 10.1038/s41379-021-00985-6. Mod Pathol. 2022. PMID: 34903824 Free article. No abstract available.
A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.
Assi R, Kantarjian HM, Garcia-Manero G, Cortes JE, Pemmaraju N, Wang X, Nogueras-Gonzalez G, Jabbour E, Bose P, Kadia T, Dinardo CD, Patel K, Bueso-Ramos C, Zhou L, Pierce S, Gergis R, Tuttle C, Borthakur G, Estrov Z, Luthra R, Hidalgo-Lopez J, Verstovsek S, Daver N. Assi R, et al. Am J Hematol. 2018 Feb;93(2):277-285. doi: 10.1002/ajh.24972. Epub 2017 Nov 27. Am J Hematol. 2018. PMID: 29134664 Free article. Clinical Trial.
Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.
Montalban-Bravo G, Takahashi K, Patel K, Wang F, Xingzhi S, Nogueras GM, Huang X, Pierola AA, Jabbour E, Colla S, Gañan-Gomez I, Borthakur G, Daver N, Estrov Z, Kadia T, Pemmaraju N, Ravandi F, Bueso-Ramos C, Chamseddine A, Konopleva M, Zhang J, Kantarjian H, Futreal A, Garcia-Manero G. Montalban-Bravo G, et al. Oncotarget. 2018 Jan 3;9(11):9714-9727. doi: 10.18632/oncotarget.23882. eCollection 2018 Feb 9. Oncotarget. 2018. PMID: 29515765 Free PMC article.
433 results